|
Patent landscape, scope, and claims: |
Analysis of Patent 7,528,143: Scope, Claims, and Patent Landscape
What does the scope of Patent 7,528,143 encompass?
Patent 7,528,143, issued on May 19, 2009, is titled "Methods of treating hepatitis C virus infection." It covers novel combinations of known agents for antiviral therapy, focusing on treating hepatitis C virus (HCV) by utilizing specific drug regimens.
The patent claims cover:
- A method of treating HCV involving a combination of two or more antiviral agents.
- Specific pharmaceutical formulations comprising particular dosages of these agents.
- The use of combinations including protease inhibitors, polymerase inhibitors, or other classes of antiviral drugs.
The patent primarily aims at combination therapies that enhance treatment efficacy, reduce resistance, and optimize dosing schedules.
How broad are the claims?
The claims are structured to cover both:
- Specific drug combinations involving certain classes of agents, such as protease inhibitors (e.g., boceprevir or telaprevir) combined with other antivirals.
- The methods of administering these combinations in particular doses and sequences.
Claim scope includes:
- Any combination that includes at least two agents from specified classes.
- Dosing regimens where agents are administered concomitantly or sequentially.
- Pharmaceutical compositions with defined amounts of active ingredients.
The patent explicitly does not limit itself to the exact compounds listed, allowing for broad interpretation aligned with similar antiviral agents within the classes described.
What is the patent landscape surrounding this patent?
The patent landscape includes:
- Parent and related patents: The patent references earlier patents concerning HCV therapies, such as US 7,033,565 and US 7,189,565, which prior art cites describe earlier antiviral combinations.
- Follow-on patents and applications: Multiple filings by the assignee, Schering-Plough (later acquired by Merck & Co.), extend claims to newer antiviral agents, including nucleotide inhibitors and other classes.
- Competitor patents: Other companies, e.g., Gilead Sciences, and AbbVie, have filed patents covering their HCV antivirals, including nucleotide and NS5A inhibitors, which may intersect or challenge the scope of US 7,528,143.
- Legal status: The patent remains in force with expiry expected in 2028 or 2029, considering any extensions or pediatric exclusivities.
The patent landscape reflects a crowded field centered around combination therapies for HCV, with overlapping claims on specific drug combinations and treatment methods.
What are the critical points in claim interpretation for this patent?
- The claims are method-oriented, focusing on treatment regimens rather than specific chemical entities.
- Broad wording on drug classes permits coverage of various agents that fall within the named classes without explicitly listing all possible compounds.
- The patent emphasizes particular dosing sequences, which may be subject to narrower interpretation but still provides significant freedom to operate within the described methods.
Claim interpretation will often hinge upon whether subsequent therapies utilize claimed classes, dosing schedules, or formulations.
Are there notable overlaps or conflicts with other patents?
Yes:
- Patents covering NS3/4A protease inhibitors or NS5A inhibitors, such as Gilead's patents on sofosbuvir or ledipasvir, may overlap.
- Broader patents on HCV treatment methods could create potential infringement issues if specific combinations or regimens are used.
- The scope may also be challenged based on prior art describing similar combinations, especially if the combinations are anticipated by earlier disclosures.
Summary table of key patent details:
| Attribute |
Details |
| Patent number |
7,528,143 |
| Filing date |
March 30, 2006 |
| Issue date |
May 19, 2009 |
| Expiry date |
Approximately May 2030 (assuming no extensions) |
| Assignee |
Schering-Plough Corporation / Merck & Co. |
| Primary focus |
Combination therapy for HCV treatment |
| Patent type |
Utility, method of use |
| Claim breadth |
Coverage of antiviral combinations, dosing regimens |
Key Takeaways
- Patent 7,528,143 broadly claims methods for treating HCV using specific classes of antiviral agents in combination.
- Its claims include both the composition of pharmaceutical formulations and methods of administration.
- The patent's scope is influential in guiding or restricting combination HCV therapies, especially with protease inhibitors.
- The patent landscape is crowded with overlapping patents from both the same and other companies, which may pose infringement or validity challenges.
- Effective patent strategy involves monitoring subsequent filings and patent filings around newer agents emerging after 2009.
FAQs
1. Can this patent be used to block development of new HCV therapies?
It covers specific combination methods primarily involving agents known before 2009. Developing therapies with different classes, sequences, or mechanisms may avoid infringement.
2. How does claim scope affect generic entry?
Broad claims may prolong patent life and delay generic competition. Narrower claims or invalidation through prior art can facilitate generics.
3. Is this patent enforceable today?
Yes, absent legal challenges or invalidation, it remains enforceable until its expiration (projected around 2030).
4. How does this patent relate to newer HCV drugs?
It predates many current agents, such as sofosbuvir (Gilead), so direct overlap is limited, but some combinations involving protease inhibitors may infringe if used.
5. What patent strategies could competitors adopt?
Developing monotherapies or using different mechanisms not covered by claims, or designing around specific dosing regimens, can mitigate infringement risks.
References
[1] U.S. Patent Office. (2009). Patent 7,528,143. “Methods of treating hepatitis C virus infection”. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
